Research Nester’s recent market research analysis on “Intravenous Pegloticase Market: Global Demand Analysis & Opportunity Outlook 2036” delivers a detailed competitors analysis and a detailed overview of the global intravenous pegloticase market in terms of market segmentation by age group, indication, end-users and by region.
Rising Consumption of Alcohol and Increasing Treatment Efficacy of Intravenous to Promote Global Market Share of Intravenous Pegloticase Market
The global intravenous pegloticase market is estimated to grow majorly on account of the increased awareness of gout illness and rising consumption of alcohol. The number of refractory gout and chronic diseases has grown noticeably in last few years. In the year 2019, the global age-standardized years lived with disability (YLDs) rates have increased from almost 9,440 years per 100,000 population. Patients from numerous groups, including pediatric, adult, and geriatric populations are included in it. This scenario shows that the global intravenous pegloticase market is anticipated to witness significant growth during the forecasted period. Apart from this, the market for intravenous pegloticase is projected to have remarkable growth opportunities on the back of the rising efforts to conduct research and development, considering the exponentially rising worldwide population. Furthermore, higher alcohol consumption is also going to fuel the growth of the intravenous pegloticase market during the anticipated period due to the association of gout diseases with drinking habits. For instance, in the year 2022, almost 63.1% of people drink alcohol and are vulnerable to getting gaut disease. On the back of this, the global intravenous pegloticase market is anticipated to garner remarkable growth during the forecasted period. The research & development are being conducted by numerous businesses in the intravenous pegloticase industry which is also acting as a growth driving factor in the global intravenous pegloticase market during the forecasted period.
Some of the major growth factors and challenges that are associated with the growth of the global intravenous pegloticase market are:
Growth Drivers:
• Surge in Alcohol Consumption Among the Population
• Rising Incidence of Gout Disease
Challenges:
Exorbitant costs associated with the treatment, side effects related to treatment, and lack of awareness are some of the major factors anticipated to hamper the global market size of the global intravenous pegloticase market.
Access our detailed report at: https://www.researchnester.com/reports/intravenous-pegloticase-market/5846
By end users, the global intravenous pegloticase market is segmented into hospital pharmacies, retail pharmacies & others. Out of these, the hospital segment is projected to garner a remarkable share of about 45.1% in the year 2036. The growth of the segment can be attributed to the rising presence of gout diseases in the adult population.
By region, the Europe intravenous pegloticase market is to generate the highest revenue by the end of 2036. The growth of the market can be attributed to increased investment in the healthcare sector leading to increased opportunities for the market players.
This report also provides the existing competitive scenario of some of the key players of the global intravenous pegloticase market which includes company profiling of Agmen Inc, BioMarin, Sarepta Therapeutics, Benitec Biopharma Inc, Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobel Pharma Co. Ltd, Santhera Pharmaceuticals, Pfizer Inc., Fibrinogen, GSK and others.